Modulating Tumor Vasculature through Signaling Inhibition to Improve Cytotoxic Therapy

Amit Maity and Eric J. Bernhard

Abstract

The tumor microenvironment is a key factor in cancer treatment response. Recent work has shown that changes in the tumor vasculature can be achieved by inhibiting tumor cell signaling, resulting in enhanced tumor oxygenation. These changes could promote responses to both chemo- and radiation therapy. Cancer Res; 70(6); OF1–3. ©2010 AACR.

Background

The tumor microenvironment (TME) presents both impediments and targets for therapy. Tumor vasculature functions poorly, with variable blood flow through leaky immature vessels, compounded by inadequate lymphatic drainage. These factors and the resultant increased interstitial fluid pressure can impede the delivery of nutrients and oxygen and reduce delivery of chemotherapy to the tumor cells (1). Decreased interstitial fluid pressure after paclitaxel treatment has been linked to increased oxygenation in breast cancer patients (2), and low interstitial fluid pressure has been associated with better prognosis in cervical cancer patients (3). Functionally impaired tumor vasculature also leads to areas in solid tumors that are nutrient-deprived, acidic, and necrotic, as well as regions exhibiting both chronic and intermittent hypoxia (4). Hypoxia, poor vascular perfusion, and reduced tumor uptake of therapeutic agents contribute to both radio- and chemotherapy treatment failure and select for more aggressive tumors (5).

The abnormalities found in tumor vessels are in large part a result of dysregulated angiogenic signaling. This signaling is initiated by tumor cell overexpression of angiogenic factors such as vascular endothelial growth factor (VEGF), which results from both TME and tumor cell oncogenic signaling (6, 7). Dysregulated angiogenic signaling leads to increased vascular permeability and aberrant vessels (Fig. 1A and B). Once established, the TME itself can act to perpetuate abnormal angiogenesis through hypoxic signaling by hypoxia-inducible factor 1 (HIF-1), a transcription factor that activates expression of dozens of genes including VEGF (8). Therapeutic intervention can also result in VEGF up-regulation through HIF-1 (9). Thus there are multiple levels during tumor development and therapy at which angiogenesis can be targeted, including the altered tumor vasculature itself, angiogenic signaling, and oncogenic signaling (Fig. 1A-D and F).

There have been two main pharmacologic approaches developed to target tumor vessels: vascular disruptive agents and anti-angiogenic agents. Vascular disruptive agents such as combretastatin A4 are designed to destroy tumors by preferentially ablating preexisting tumor vessels (10). However, these agents are limited by the presence of collateral supplies to the tumor periphery from the surrounding normal tissue vasculature. Furthermore, these agents may exacerbate hypoxia.

Another means of altering the TME was proposed in the 1970s by Judah Folkman, who suggested targeting new vessel growth (angiogenesis) as a strategy to control the growth of cancers (11). Anti-angiogenic agents inhibit the action of factors that stimulate new blood vessel development (12). There are currently a number of anti-angiogenic approaches including anti-VEGF receptor antibodies, VEGF traps, and inhibitors of VEGF kinase activity in various stages of development and in clinical trials (reviewed in ref. 13). Unfortunately, success to date using VEGF blockers as single agents has been limited (14). Possible reasons include development of resistance to anti-angiogenic inhibitors via up-regulation of redundant angiogenic pathways and increased tumor metastatic potential (reviewed in ref. 15).

Investigations into the combined use of anti-VEGF agents with cytotoxic therapies have yielded more promising results than VEGF-targeting monotherapy. Preclinical work has shown that VEGF can be induced in response to radiation and that inhibition of VEGF can increase tumor control after radiation (16). There has been a great deal of interest in studying the combined use of the anti-VEGF monoclonal antibody bevacizumab (Avastin) with other cytotoxic agents. Early success was seen using combined treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (17). Bevacizumab has shown
efficacy in combination with conventional chemotherapy in other cancers although the results have generally been modest, with small improvements in overall survival at best and sometimes only in progression-free survival (18, 19). The toxicity of Bevacizumab in combination with radiotherapy has also been a concern (20).

How does anti-VEGF therapy potentiate cell killing in response to cytotoxic therapy? VEGF receptor inhibition reduces endothelial cell proliferation in vitro after irradiation and also reduces microvessel density in irradiated tumors (21). Thus it may sensitize tumor endothelial cells to cell death in response to radiation. However, there may be additional mechanisms at work. Jain and coworkers have shown that blocking VEGF signaling with DC101, a VEGF receptor-2 (VEGFR-2) antibody, decreased interstitial fluid pressure in xenografts in mice by producing a morphologically and functionally “normalized” vascular network (22). Furthermore, DC101 induced a hydrostatic pressure gradient across the vascular wall, which led to deeper penetration of molecules into tumors. Vascular normalization may in fact be a prognostic marker for treatment response (23). This “vascular normalization” is accompanied by a transient reduction in tumor hypoxia and enhanced vascular flow and diffusion (24). The normalization period offers an opportunity for enhanced efficacy of radiation and chemotherapy, but this period is relatively short and followed by vascular insufficiency owing to strong and prolonged anti-angiogenic activity using current approaches. In addition, vascular normalization has not been observed in all studies (reviewed in ref. 10).

An Alternative Strategy: Inhibiting Oncogenic Signaling in Cancer Cells

The approach used by Jain and colleagues relies on using agents that directly target VEGF or VEGFR on
endothelial cells. Another strategy is to indirectly target VEGF by inhibiting oncogenic signaling in cancer cells, hence decreasing both oncogenic activity and VEGF secretion. Two studies have recently appeared that highlight this approach (25, 26). Both studies arose out of attempts to target tumor cells for sensitization to radiation and cytotoxic drugs. In the course of studying the effects of signaling inhibition on tumor sensitivity in vivo, significant changes in tumor oxygenation were seen (27). These observations led to investigation of the mechanisms for the vascular changes induced by oncogene signaling inhibition (28), and to definition of the important targets for this inhibition in the EGFR to AKT signaling pathway (25, 29). Qayum and colleagues showed that in cells with activation of EGFR to AKT signaling, inhibition at multiple points in this signaling pathway resulted in prolonged enhancement of vascular function accompanied by decreased hypoxia and enhanced diffusion of small molecules into the tumor stroma. Vessels in treated tumors were less tortuous, and showed markers indicating a more mature phenotype. This finding was seen in both xenografts and spontaneous tumor models. The study by Cerniglia and colleagues (26) using the EGFR inhibitor erlotinib reached similar conclusions. They showed that erlotinib led to decreased VEGF secretion by cancer cells. Erlotinib treatment of mice bearing xenografts enhanced vascular functioning in the tumors, as measured by blood flow and also improved oxygenation. Extending these findings, they showed increased delivery of the cytotoxic drug cisplatin to the tumors when mice were pretreated with erlotinib for 4 days prior to cisplatin injection. This resulted in tumor growth delay that was greater than that seen after the order of the treatments was reversed, i.e., cisplatin followed by erlotinib treatment. Thus, these parallel studies have shown that inhibition of tyrosine kinase receptor signaling through RAS, PI3-Kinase, and AKT results in enhanced vascular function (Fig. IA-F). As a further consequence, this normalization enhances tumor oxygenation and the delivery of cytotoxic drugs that may promote antitumor activity (Fig. IA-G). Preliminary findings indicate that a similar potentiation of tumor radiation response is likely.3

These two studies show that using agents that inhibit oncogenic signaling in tumor cells can lead to vascular changes consistent with vascular normalization. The results are similar to those observed after direct inhibition of VEGF signaling, but show more prolonged effects on the TME. This raises the as-yet-unanswered question of whether a lower dose of directly anti-angiogenic treatment could yield prolonged enhancement of vascular function? Conversely, experiments by Izumi and colleagues (30) and others, using higher doses of signaling inhibitors, have resulted in anti-angiogenic effects. So it is apparent that the application of signaling inhibitors at high doses (such as one might achieve if aiming for a maximally tolerated dose) might be counter-productive from the point of view of effects on the TME.

Are there advantages to signaling inhibition over direct anti-angiogenic approaches? Inhibition of oncogenic signaling often increases the intrinsic sensitivity of the cancer cells independent of the TME (31, 32), whereas direct and specific anti-angiogenic therapy does not. This enhanced tumor cell susceptibility to cytotoxic treatment could add to the effects of improved tumor vascular function and counter any advantage to tumor growth imparted by the enhanced oxygen and nutrient supplies during cytotoxic therapy. Secondly, inhibition of oncogenic signaling might have the advantage of a wider dose-response range for vascular effects because of the partial down-regulation of VEGF expression achieved by this approach. For example, both Cerniglia and colleagues and Qayum and colleagues found that treatment of cancer cells with EGFR inhibitors or nelfinavir resulted in only a partial decrease in VEGF expression (25, 26). Anti-angiogenic agents are designed to work by potently and completely inhibiting VEGF signaling. They therefore have the potential to severely compromise vascular function and drug delivery on the one hand and increase hypoxia and reduce radiation efficacy unless administered at precisely the right doses and times relative to radiation or cytotoxic drug treatments. In clinical practice, such precise timing and dosing may be very difficult to achieve. An alternative approach to the use of anti-angiogenics could be to administer these agents after completion of cytotoxic therapies to inhibit the repair of tumor vascular damage and tumor regrowth.

Clinical Implications

These findings may have important clinical implications. Increasing blood flow through the tumor vessels should lead to improved drug delivery. Increased oxygenation during radiotherapy should enhance radiation response. Preclinical data support these predictions and offer a rationale of why the optimal time to start these inhibitors of oncogenic signaling might be 1 week or so prior to cytotoxic therapy. Furthermore, if changes in the TME are important for the efficacy of subsequent cytotoxic therapy, then the TME could be imaged prior to and after 5-10 days of inhibitor treatment, to determine whether there has been any modulation of the TME and to determine whether this change could predict outcome. One report showing a positive correlation between vascular normalization and treatment outcome has already appeared (23). The technology to monitor these changes exists and could be used to assess tumor vascularity (e.g., dynamic contrast-enhanced magnetic resonance imaging, Power Doppler) and/or oxygenation changes (e.g., positron emission tomography scanning with hypoxia-sensitive tracers, electron paramagnetic resonance oximetry; refs. 33, 34). These techniques may help to answer the question of how long enhanced vascular function persists in human tumors, and to address how cytotoxic therapies affect the vascular changes induced by signaling inhibitors.

It is of interest to note that other approaches to altering tumor vasculature are being reported. The integrin

---

3 E.J. Bernhard and N. Qayum, unpublished observations.
antagonist cilengitide has been shown to have similar effects to signaling inhibition on tumor vascular morphology (35). Inhibition of Hedgehog signaling has also been recently shown to enhance delivery of gemcitabine to pancreatic tumors in mice (36). Whether these approaches will be applicable to a wide range of tumor types is not yet known. Thus there may be other options available for achieving enhanced vascular function in tumors should this be shown to be of benefit to therapy. Which of these options will be most effective in enhancing tumor cell killing by cytotoxic therapies remains to be determined. Together, these recent studies further point to the need to examine the effects of signaling inhibition on the TME when evaluating the effects of signaling inhibitors on cancer growth and radio- or chemotherapy treatment responses.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
We wish to thank Drs. Helen Stone and Bhadrasian Vikram for helpful comments. We apologize to authors whose work was not cited because of restraints on article length.

Grant Support
Grants from the National Institutes of Health (NIH): CA093638 (A. Maity), CA73820 (E.J. Bernhard), and MRC (E.J. Bernhard) during the studies described in this report.

Received 10/14/2009; revised 12/02/2009; accepted 12/03/2009; published OnlineFirst 02/23/2010.

References
29. Prevo R, Deutsch E, Sampson O, et al. Class I PI3 kinase inhibition...


Modulating Tumor Vasculature through Signaling Inhibition to Improve Cytotoxic Therapy

Amit Maity and Eric J. Bernhard

Cancer Res  Published OnlineFirst February 23, 2010.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-09-3615

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.